Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Coty Campbell

Nurse Practitioner, Family Columbia, SC Nurse Practitioner

NPI 1265579106 CMS profile 10443022

1600 Lake Murray Blvd, Columbia, SC 29212

Open in the dashboard

General payments

$11,339

707 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Coty Campbell of Columbia, SC is reported in the CMS Open Payments database as having received $11,339 across 707 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,588 231
2024 General $2,902 169
2023 General $2,179 140
2022 General $1,434 88
2021 General $1,236 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Coty Campbell
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Coty Campbell were reported at $3,588. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Coty Campbell Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,236 $124 $35–$379 $132
2022 $1,434 $141 $44–$430 $149
2023 $2,179 $154 $49–$476 $160
2024 $2,902 $165 $51–$504 $164
2025 $3,588 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,990 148 payments
  2. Janssen Biotech, Inc. $1,577 86 payments
  3. UCB, Inc. $958 38 payments
  4. Lilly USA, LLC $794 39 payments
  5. Regeneron Healthcare Solutions, Inc. $733 41 payments
  6. Pfizer Inc. $676 35 payments
  7. Novartis Pharmaceuticals Corporation $496 32 payments
  8. Amgen Inc. $458 23 payments
  9. Sun Pharmaceutical Industries Inc. $424 18 payments
  10. LEO Pharma Inc. $402 19 payments
  11. Other $2,833 228 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,189 705 payments
  2. Education $150 2 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,345 74 payments
  2. Bimzelx $727 27 payments
  3. SKYRIZI $682 62 payments
  4. RINVOQ $657 38 payments
  5. CIBINQO $605 30 payments
  6. DUPIXENT Inflammation And Immunology $504 29 payments
  7. TALTZ $500 22 payments
  8. DUPIXENT Immunology $493 34 payments
  9. Otezla $458 23 payments
  10. VTAMA $443 52 payments
  11. Other $7,287 451 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

2,267

Median for Nurse Practitioner: 389

Drug cost

$264,508

Median for Nurse Practitioner: $21,885

Branded share of claims

8.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Opzelura Ruxolitinib Phosphate Brand 55 $111,565
Humira(Cf) Pen Adalimumab Brand 11 $71,377
Zoryve Roflumilast Brand 22 $18,782
Vtama Tapinarof Brand 14 $18,742
Ketoconazole Generic 347 $5,868
Ivermectin Generic 23 $4,570
Mupirocin Generic 632 $4,515
Tretinoin Generic 68 $3,963
Clindamycin Phosphate Generic 129 $3,518
Clobetasol Propionate Generic 87 $2,974

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$131,213

Of which drugs: $95

Medicare patients

758

Average age 73

Services billed

4,240

431 women, 327 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 42%
Diabetes 25%
Ischemic heart disease 24%
Chronic kidney disease 17%
Depression 16%
Atrial fibrillation 15%
Cancer 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 42 146 $95

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Bimzelx
$368 — —
TREMFYA
$329 — —
VTAMA
$317 14 —
DUPIXENT
$220 — —
RINVOQ
$208 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

707 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record